ProstaScore®

A Tissue-Based Test to Predict Progression in Prostate Cancer

Description

- Tissue-based genetic testing using next-generation sequencing (NGS)
- RNA sequencing analysis (RNA-seq) to measure gene expression across the transcriptome
- Panel of RNA biomarkers to accurately identify prostate cancers with low risk of progression
- ProstaScore™ software for standardized result interpretation and reporting

Workflow



Clinical Benefit

- Predicts the risk of progression within five years from the tumour diagnosis by biopsy
- Predicts the risk of pelvic lymph node invasion within three years from the tumour diagnosis by biopsy
- May help avoid unnecessary radical prostatectomy and extensive lymph node dissection
- Reduces overdiagnosis and overtreatment
- Suitable for implementation in clinical laboratories

Patent

Molecular signature and use thereof for the identification of indolent prostate cancer.
EP 19 701 362.6 – US 12,123,058 – CA 3 089 406 – JP 2020-560 592

Publications

Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Annals of Oncology 29: 1814–1821, 2018

Evaluation of ProstaScore™ and Magnetic Resonance Imaging for preoperative prediction of Lymph Node Involvement determined by Extended Lymph Node Dissection. 41st Annual EAU Congress (EAU26)-London on 13-16 March, 2026

OncoDiag
www.oncodiag.fr
251 rue Clément Ader – 27000 Evreux -France
hennion@oncodiag.fr